By binding to RANKL, a key mediator of differentiation, function, and survival of osteoclasts, denosumab works through a different pathway from BPs to increase BMD and reduce the fracture incidence in patients with osteoporosis (18, 19). This evidence concerns the gene TNFSF11 and osteoporosis.